We compared the prognostic value of conventional cytogenetic analysis and established factors such as ␤ 2 -microglobulin and plasma cell labeling index in 70 patients undergoing autologous blood cell transplantation for multiple myeloma. Patients underwent transplantation 5 to 88 months (median, 20 months) after the initial diagnosis of myeloma. Factors studied were age, sex, ␤ 2 -microglobulin, response to prior therapy, plasma cell labeling index, cytogenetic analysis, bone marrow plasma cell percentage, lactate dehydrogenase and C-reactive protein. Twenty-eight of 65 patients (43%) had abnormal marrow cytogenetics. Overall survival measured from transplantation was significantly better in patients with normal cytogenetics than in those with abnormal cytogenetics (median survival, 25 vs 12 months, P = 0.003). Progression-free survival was better, with median times of 12 vs 7 months, respectively (P = 0.005); overall survival measured from the time myeloma was first diagnosed was also longer, with median survivals of 62 and 39 months, respectively (P = 0.001). Median plasma cell labeling index was 1.5% in patients with abnormal cytogenetics and 0.2% in those with normal cytogenetics (P Ͻ 0.001). Abnormal bone marrow cytogenetics predict poor survival after blood cell transplantation for myeloma. There is a significant correlation between abnormal cytogenetics and high plasma cell labeling index, suggesting that certain cytogenetic abnormalities may offer a proliferative advantage to myeloma cells. Keywords: autologous blood cell transplantation; cytogenetics; multiple myeloma Multiple myeloma accounts for 1% of all malignancies, 2% of all cancer deaths, and 10% of malignant hematologic neoplasms.
High-dose chemotherapy, with or without total body irradiation, followed by autologous stem cell transplantation is an alternative to conventional chemotherapy and improves survival in selected patients. 3, 4 A recent randomized trial 5 in previously untreated patients with myeloma showed superior results with autologous transplantation compared with conventional chemotherapy. In this trial, overall survival at 5 years was 52% with transplantation and 12% with conventional chemotherapy.
Transplantation is not curative. Almost all transplant patients eventually relapse, and there is no plateau in the survival curves. 3 Although many centers offer transplantation to newly diagnosed patients, it is possible that transplantation can be delayed until patients fail to respond to conventional chemotherapy, if stem cells are collected early in the disease course. A recent French randomized trial has reported no significant difference in survival between early and delayed transplant. 6 With the delayed approach, newly diagnosed patients are treated for a few months with chemotherapy that is not toxic to stem cells to minimize tumor burden, and then blood stem cells are mobilized and cryopreserved for future use. Patients continue on conventional chemotherapy until relapse or progression, at which point a transplant is considered.
There is significant variation in survival of patients with myeloma, and approximately 3% of patients live more than 10 years. 7 Two important predictors of survival in conventionally treated patients with myeloma are serum ␤ 2 -microglobulin (␤ 2 M) concentration and bone marrow plasma cell labeling index (PCLI). 8 However, PCLI is not readily available in most centers. Other predictors include age, lactate dehydrogenase (LDH) and C-reactive protein (CRP). 8, 9 Identifying prognostic factors in patients being considered for transplant is critical. Cytogenetic analysis is commonly performed before transplant and is widely available. In this study we assess the prognostic value of pretransplant bone marrow cytogenetics in patients undergoing stem cell transplants at the Mayo Clinic.
Patients and methods
Seventy patients underwent high-dose therapy and blood cell transplantation for myeloma at the Mayo Clinic between June 1989 and August 1997. Data from these patients were collected prospectively and entered into a comprehensive computerized database. Information regard- Stem cells were harvested in most patients after initial chemotherapy with vincristine, doxorubicin and dexamethasone. Only three patients underwent transplantation in the plateau phase of myeloma; the rest had relapsed during or after prior chemotherapy or had primary chemorefractory disease. The conditioning regimen (high-dose therapy) consisted of melphalan (140 mg/m 2 ) and total body irradiation in 53 patients. Some patients received melphalan, cyclophosphamide, and total body irradiation (11 patients) or melphalan (200 mg/m 2 ) alone (three patients). Three patients received other regimens. After high-dose therapy, all patients had stem cells reinfused, except for one patient (included in the analysis) who died of sepsis 1 day before stem cell infusion.
498
After transplantation, complete response was defined as lack of detectable monoclonal (M) protein in serum or urine by immunoelectrophoresis and immunofixation, with normalization of bone marrow. Partial response was defined as reduction of serum M protein and 24-h urinary light chain excretion by at least 50% accompanied by a similar reduction in soft-tissue plasmacytomas, if present. Patients with urine light chain only must have reduction of urinary light chain excretion to 10% or less of the pretreatment value.
Relapse (or progression in the case of partial responders) after transplant was defined as a 50% increase in the serum 499 Table 3 Univariate comparisons: overall survival and progression-free survival PCLI is a measurement of the proliferative activity of the monoclonal plasma cells. 8, 10, 11 The assay can be done on both bone marrow and peripheral blood. PCLI was performed using a slide-based immunofluorescence method on bone marrow samples before transplant as described elsewhere. 8, 11 A PCLI у 1% is classified as high. For cytogenetic analysis, bone marrow specimens were processed by direct and short-term culture techniques, as described previously.
12,13 Each of our patients had at least 20 QFQ-banded (Q bands using fluorescence by quinacrine mustard) or GTL-banded (G bands using trypsin and Leishman's stain) metaphase specimens (or both) analyzed. Representative karyotypes were prepared from at least two metaphase specimens for each sample. Each karyotype was described according to the International System for Human Cytogenetics Nomenclature (ISCN 1995). 12 Survival analysis used the method described by Kaplan and Meier. 14 Differences between survival curves were tested for statistical significance using the two-tailed logrank test. The following prognostic factors for overall and PFS after transplant were tested in a univariate analysis: age, sex, ␤ 2 M, CRP, time to transplant from initial diagnosis, response to prior chemotherapy, PCLI and bone marrow cytogenetics. Factors that significantly predicted survival after transplant in the univariate model were studied in a multivariate analysis using Cox's proportional-hazards model. 15 The relationships between individual variables and risk were examined using the residual plots of Grambsch et al. 16 The rank-sum test was used to compare differences in PCLI among patients with normal and abnormal cytogenetics.
Results
Forty-eight men and 22 women, ages 33 to 69 years (median, 53 years), were studied. Patient characteristics are listed in Table 1 . Patients underwent transplantation 5 to 88 months (median, 20 months) after the initial diagnosis of myeloma. At the time of transplant, 67 patients (96%) had relapsed or had refractory disease.
The serum M protein spike ranged from 0.0 to 10.0 g/dl (median, 2.0 g/dl). Median bone marrow plasma cell involvement was 30%. Serum ␤ 2 M was Ͼ2.7 mg/l in 63% and PCLI was у1% in 47% of patients.
Forty-two patients have died. Recurrent myeloma was the cause of death in 32 patients. Seven patients died of transplant-related complications and one each of intracranial bleed, acute myeloid leukemia, and suicide. Median survival after transplantation was 17 months for the cohort. Progression-free survival was 9 months.
Cytogenetic analysis
Twenty-eight of 65 patients (43%) had abnormal marrow cytogenetics, and most abnormalities (93%) were complex (у3 abnormalities) ( Table 2 ). This included deletions of chromosome 13 (46%) or 11 (25%) and translocations (29%). Abnormalities of chromosome 13 or 11 or translocations were present in 89% of patients with cytogenetic abnormalities. Translocations were present in 29% of those with abnormal cytogenetics, including three patients who had translocations involving the immunoglobulin heavy chain region on chromosome 14.
Univariate analysis
Univariate survival comparisons are shown in Table 3 for overall survival and PFS. Age, sex, ␤ 2 M, CRP, and time from initial diagnosis and response to prior chemotherapy did not predict survival or progression. Lack of a prior response to chemotherapy may be an important favorable prognostic variable but was not statistically significant for overall survival. Overall survival after blood cell transplantation was significantly longer in patients with normal than in those with abnormal cytogenetics, with median survivals of 25 and 12 months, respectively (P = 0.003) (Figure 1a) . PFS also was significantly longer in patients with normal cytogenetics, with median times of 12 and 7 months, respectively (P = 0.005) (Figure 1b) . Owing to the small sample size, we did not attempt to assess the effect of specific cytogenetic abnormalities on survival. Early mortality was not increased in the group with abnormal cytogenetics. Of the seven early deaths due to transplant-related causes, two patients had abnormal cytogenetics and five had normal cytogenetics.
The PCLI also was a significant predictor for survival. Median survival was 11 months in patients with a PCLI у 1% vs 24 months in those with PCLI Ͻ 1% (P = 0.006) (Figure 2a ). PFS also was significantly different, with median times of 7 and 12 months, respectively (P Ͻ 0.001) (Figure 2b) . In an exploratory analysis, it appears that risk of failure increases steadily with an increasing PCLI (from 0% to 2%) and then reaches a plateau for patients with and without cytogenetic abnormalities. Overall survival between those with low (Ͻ1%) and high (у1%) plasma cell labeling index (PCLI) was 24 and 11 months, respectively; progressionfree survival was 12 and 7 months, respectively. 
Multivariate analysis
Abnormal cytogenetics and PCLI were highly related. Median PCLI was 1.5% in patients with abnormal cytogenetics and 0.2% in patients with normal cytogenetics (P Ͻ 0.001) (Figure 3 ). All 12 patients with PCLI у 2% had abnormal cytogenetics.
The PCLI does not add significant predictive value to a model that already contains cytogenetics and vice versa, for both overall survival and PFS. We noted a trend toward poorer survival with an increasing PCLI up to a value of approximately 2% among patients with and without normal cytogenetics. This suggests that the PCLI may have prognostic value independent of cytogenetics that did not reach statistical significance.
None of the variables that were nonsignificant in the univariate model were important in the multivariate analysis.
Discussion
Cytogenetic abnormalities are of major prognostic significance in acute leukemias and myelodysplastic syndromes. The prognostic value of conventional cytogenetic analysis in patients with myeloma on standard chemotherapy has been studied but is of doubtful significance. 9, 17 Owing to the low proliferative activity of neoplastic cells in newly diagnosed myeloma, it is difficult to demonstrate cytogenetic abnormalities in most patients by conventional karyotypic methods. 18 Among patients with abnormal cytogenetics, most have multiple and complex abnormalities. 19 The types of abnormalities found in this study are typical of what has been observed by others. Earlier studies found that cytogenetic abnormalities are more frequent in relapsed than in newly diagnosed patients. 17, 19, 20 Our study population consisted of patients primarily with relapsed or refractory disease, explaining the high percentage (43%) of patients with abnormal cytogenetics by conventional methods.
This study shows that abnormal cytogenetics at the time of transplantation is a major prognostic factor for overall survival and PFS in previously treated patients undergoing blood cell transplantation for myeloma. Patients with abnormal cytogenetics do poorly, with a median survival of 1 year and PFS of 7 months after transplantation.
Our study confirms an earlier report by Tricot and colleagues 21 of an important role for cytogenetics in predicting outcome in patients undergoing autologous, tandem (double) transplants for myeloma. In their study of 427 patients, those with abnormal cytogenetics at transplantation had a significantly worse outcome than those with normal cytogenetics: overall survival 29 vs 55 months and event-free survival 19 vs 36 months, respectively. In subset analysis, among patients with abnormal cytogenetics, those with translocations or abnormalities of chromosome 11 or 13 (unfavorable karyotypes) had the worst outcome. 21 In multivariate analysis, presence of an unfavorable karyotype was the most important predictor of poor overall and eventfree survival. They also found duration of prior therapy (Ͼ12 months), increased ␤ 2 M concentration (Ͼ2.5 mg/l) and CRP concentration (Ͼ4 mg/l) were independent predictors of an adverse outcome.
Simpson and colleagues 22 have reported in abstract form a study of 123 patients with myeloma referred for stem cell transplants. They found cytogenetic abnormalities in 27%. Patients with abnormal cytogenetics had a median survival from diagnosis of myeloma of 42 months compared with 87 months for those with a normal karyotype (P Ͻ 0.01). Abnormalities of chromosome 1, 11 or 13 were each associated with poor outcome. Eleven patients with abnormal cytogenetics in their study went on to transplantation, and none lived more than 2 years. In comparison, 42 patients with a normal karyotype went on to transplantation, and 85% lived more than 2 years (P = 0.02).
Survival in our study is shorter than that reported in both of the studies discussed above. This probably reflects patient selection and timing of transplantation. Ninety-six percent of patients studied by us had refractory or relapsed disease at transplantation and 83% had received two or more chemotherapy regimens before transplantation. In contrast, more than 25% of patients studied by Tricot and colleagues 21 had newly diagnosed myeloma. More than 80% of patients in the present study had Durie-Salmon stage III disease at transplantation compared with less than 50% of patients in the other studies. Furthermore, Simpson and colleagues 22 reported survival in months from initial diagnosis of myeloma, whereas we report survival from date of transplantation. Time from diagnosis to transplantation ranged from 5 to 88 months (median, 20 months) in our study. When we studied survival from time of diagnosis of myeloma, patients with abnormal cytogenetics had a median survival of 39 months compared with 62 months in those with normal cytogenetics (P = 0.001).
Our findings suggest that the presence of any cytogenetic abnormality confers an adverse outcome. We did not have a sufficient sample size to assess the prognostic significance of specific chromosomal abnormalities. Translocations and abnormalities of chromosomes 11 and 13 have been shown to be chiefly responsible for the adverse prognostic effect of abnormal cytogenetics. 21, 23 Although we did not confirm this finding, nearly 90% of patients with abnormal cytogenetics we studied had abnormalities of chromosome 11 or 13; our ability to study the effect of other cytogenetic abnormalities on outcome was limited.
Conventional cytogenetic analysis is not sensitive in identifying chromosomal abnormalities in myeloma for reasons discussed earlier. Investigators have grown bone marrow cells from patients with myeloma in cytokinestimulated cultures to improve myeloma cell growth; 51% of patients with myeloma were found to have cytogenetic abnormalities. 20 Abnormalities were more frequent in relapsed (69%) than in newly diagnosed myeloma (46%). Others have used fluorescent in situ hybridization techniques and found immunoglobulin heavy chain gene translocations (14q32.33) in 65% of patients with normal cytogenetics by conventional methods. 24 Using fluorescent in situ hybridization techniques with simultaneous cytoplasmic immunoglobulin staining, we noted numeric cytogenetic abnormalities in 61% of patients with normal findings on conventional cytogenetic analysis. 25 With these improved techniques, it will be possible to study the prognostic value of specific cytogenetic abnormalities and to assess their functional and molecular significance.
There are several mechanisms by which abnormal cytogenetics leads to a poor outcome after transplantation. Some abnormalities probably cause more aggressive tumor cell growth. There is evidence favoring this hypothesis in the present study from our finding that patients with abnormal cytogenetics have a significantly higher PCLI. On the other hand, more metaphases are available for cytogenetic analysis in the presence of a high PCLI, making cytogenetic abnormalities easier to detect on conventional karyotypic studies. Owing to the multiple and complex nature of chromosomal abnormalities that occur, it is not possible to predict the functional significance of individual aberrations at present. Some have postulated that because abnormalities of chromosomes 11 and 13 are particularly unfavorable, deletions of tumor-suppressor genes on these chromosomes may be involved, including the retinoblastoma gene (Rb-1, chromosome 13) and the mixed lineage leukemia gene (MLL, 11q23) . 21 Similarly, translocations that need to be studied include those involving the cyclin D 1 oncogene t (11;14) that is overexpressed in mantle cell lymphoma and translocations involving the immunoglobulin heavy chain gene (chromosome 14q).
PCLI is of proven prognostic value in myeloma. 8 We found this to be true in our study as well. In fact, in multivariate analysis, we were unable to show a prognostic value of cytogenetics independent of PCLI and vice versa. However, observed trends toward independent significance for both variables did not reach statistical significance because of the relatively small sample size in our study. Cytogenetic analysis is more readily available than PCLI and will be of greater relevance to practicing clinicians. However, cytogenetic analysis in myeloma requires significant expertise and the paucity of metaphases makes this even more challenging.
Although we did not find ␤ 2 M to be a significant prognostic factor, this may reflect sample size issues and is a limitation of our study. Lack of a prior response was associated with a trend to better overall and progression-free survival, probably because these patients respond well to dose intensification and had a lesser degree of prior treatment.
Patients with abnormal cytogenetics and other poor prognostic factors may benefit from inclusion in innovative trials, such as those using biologic agents or monoclonal antibodies instead of or in addition to transplantation. More studies are needed to identify better conditioning regimens, 26 decrease contamination of reinfused stem cells (eg through CD34 selection) 27 and define the role of allogeneic bone marrow transplantation 28, 29 in myeloma. Physicians and patients should take results of pretransplant cytogenetic analysis into account when considering transplantation.
